Bio-Rad Laboratories, Inc. (BIO)
Market Cap | 13.67B |
Revenue (ttm) | 2.80B |
Net Income (ttm) | -6.03B |
Shares Out | 29.24M |
EPS (ttm) | -201.41 |
PE Ratio | n/a |
Forward PE | 28.01 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 167,195 |
Open | 466.43 |
Previous Close | 464.26 |
Day's Range | 456.67 - 470.92 |
52-Week Range | 344.63 - 670.62 |
Beta | 0.90 |
Analysts | Buy |
Price Target | 602.82 (+28.96%) |
Earnings Date | Feb 16, 2023 |
About BIO
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics,... [Read more]
Financial Performance
In 2021, BIO's revenue was $2.92 billion, an increase of 14.81% compared to the previous year's $2.55 billion. Earnings were $4.25 billion, an increase of 11.55%.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for BIO stock is "Buy." The 12-month stock price forecast is $602.82, which is an increase of 28.96% from the latest price.
News

Bio-Rad to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for t...

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now
Investors are optimistic about Bio-Rad (BIO), led by robust demand in the Life Science and Clinical Diagnostics arms.

Bio-Rad to Present Company Overview at J.P. Morgan 41st Annual Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that Norman Schwartz, P...

Bio-Rad (BIO) Core Diagnostic Sales Grow Amid Supply Challenges
Bio-Rad's (BIO) underlying Life Science currency-neutral core revenue growth is primarily driven by Western loading, qPCR, process media and antibody products sales.

Bio-Rad To Participate in Fireside Chat During Credit Suisse's 31st Annual Healthcare Conference
HERCULES, Calif.

Bio-Rad (BIO) Q3 Earnings Surpass Estimates, Margins Down
Bio-Rad's (BIO) third-quarter revenues decline mainly as a result of lower COVID-related sales compared with the year-ago period.

Bio-Rad Laboratories (BIO) Surpasses Q3 Earnings Estimates
Bio-Rad (BIO) delivered earnings and revenue surprises of 0.39% and 1.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad to Report Third Quarter 2022 Financial Results on Thursday, October 27, 2022
HERCULES, Calif.

Should You Buy Bio-Rad Laboratories Stock After Its 50% Fall This Year?
Bio-Rad Laboratories stock (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 48% fall this year, significantly underperforming the broader S&P500 index, down 24...

Bio-Rad and German-based biotech Qiagen weighing latest tie-up in medical-diagnostic market
Bio-Rad Laboratories Inc. is in talks to combine with fellow life-sciences company Qiagen NV in a deal that would be worth more than $10 billion, according to people familiar with the matter.

Diagnostics firm Bio-Rad in talks to merge with Qiagen - WSJ
California-based diagnostics company Bio-Rad Laboratories is in talks to merge with Qiagen NV , the Wall Street Journal reported on Monday, citing people familiar with the matter.

Bio-Rad Laboratories in Talks to Combine With Qiagen
Bio-Rad Laboratories Inc. is in talks to combine with fellow life-sciences company Qiagen NV in a deal that would be worth more than $10 billion, according to people familiar with the matter.

Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
Investors are optimistic about Bio-Rad's (BIO) better-than-expected results and continued growth across major geographies.

4 Stocks to Watch Amid Recovering Medical Products Industry
Despite the COVID-induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ZBH, BIO, LNTH and HAE are well-poised ...

Bio-Rad Acquires Curiosity Diagnostics
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an ag...

Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Gross Margin Up
Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.

Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings and Revenue Estimates
Bio-Rad (BIO) delivered earnings and revenue surprises of 37.40% and 3.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Reports Second-Quarter 2022 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the...

Bio-Rad to Report Second Quarter 2022 Financial Results on Thursday, July 28, 2022
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the...

Bio-Rad Publishes Corporate Sustainability Report
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today released its inaugural corporate su...

Bio-Rad (BIO) Immunohematology Arm Recovers, New Launches Aid
Bio-Rad's (BIO) qPCR business is experiencing excellent uptake from the new-generation CFX Opus platform.

Wall Street Analysts Believe Bio-Rad (BIO) Could Rally 53%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 52.9% in Bio-Rad (BIO). While the effectiveness of this highly sought-after metric is questionable, the positiv...

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up
Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.